semaglutide for diabetes wichita FDA Clears Cardiac Risk Reduction in Diabetic Patients Wegovy® Semaglutide 0.25 mg /

doi:10.1136/bmjopen-2020-048575 [PubMed] Fan, R., Zhang, A., & Zhong, F

Placebo-controlled trials similarly suggested higher effectiveness of tirzepatide, but study designs differed so results were not directly comparable, Rodriguez said

Nausea is one of the most frequently reported adverse effects of this medication class, occurring because GLP-1 agonists slow gastric emptyinga mechanism that improves glycaemic control but can cause gastrointestinal discomfort

Research suggests that the healthcare industry treats fat patients worse than skinny ones and that fat people are also discriminated against at work and school

Qsymia (phentermine and topiramate) is an FDA-approved extended-release weight loss medication